Zobrazeno 1 - 10
of 191
pro vyhledávání: '"Treatment-related adverse events"'
Autor:
Zhibin Chang, Mingming Li, Zhicheng Sun, Zhaogang Liu, Yue Yang, Lei Xu, Lei Li, Chengsheng Zhang, Pengfei Sun, Jingtao Zhong, Bo Zhang, Xuetao Shi, Kai Cui, Jianxin Zhang, Zhongchao Li, Lei Zhao
Publikováno v:
BMC Gastroenterology, Vol 24, Iss 1, Pp 1-14 (2024)
Abstract Aim The purpose of this study was to interpret real-world clinical data to analyze the surgical safety and survival outcomes of patients with initial unresectable hepatocellular carcinoma (uHCC) after conversion therapy. Methods A retrospect
Externí odkaz:
https://doaj.org/article/fba405dfd44a41d6b033aa9f24de51e9
Autor:
Yi-Ming Ma, Shu-Xia Cheng, Ming-Chuan Zhang, Hui-Ying Zhang, Jun-Jiao Gu, Pan-Pan Zhao, Hong Ge
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
PurposeThis study compared the timing effects of immune checkpoint inhibitor (ICIs) administration on the efficacy and safety of concurrent chemoradiotherapy for cervical cancer.MethodsThis study included patients with advanced cervical cancer who re
Externí odkaz:
https://doaj.org/article/9c02e653dcee4dda9904616d816432b9
Publikováno v:
BMC Medicine, Vol 22, Iss 1, Pp 1-9 (2024)
Abstract Background Immune checkpoint inhibitors (ICIs) have transformed tumor treatment. However, the risk of pulmonary adverse events (PAEs) associated with ICI combination therapy is still unclear. We aimed to provide a PAE overview and risk order
Externí odkaz:
https://doaj.org/article/3fd1d5a5620d492cb37e25dfea2bf2ce
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
AimThis study comprehensively assesses the incidence and profiles of treatment-related adverse events (trAEs) of immune checkpoint inhibitor (ICI)-based therapies across cancer at various sites.MethodsWe systematically searched the PubMed, Embase, an
Externí odkaz:
https://doaj.org/article/8fe28a470c0f4b7090d8884a575ac2b4
Publikováno v:
Cancer Medicine, Vol 13, Iss 7, Pp n/a-n/a (2024)
Abstract Background Immune checkpoint inhibitors (ICIs) are widely used in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC); however, the toxicity profiles are inconclusive. Methods Clinical trials evaluating ICIs for R/M HNS
Externí odkaz:
https://doaj.org/article/1e34093fea6c42cdaa280c6e7b5fa0e0
Autor:
Xiao-Han Zhao, Hong-Mei Gao, Jing-Yuan Wen, He-Song Wang, Luan-Ying Wu, Chun-Yang Song, Wen-Zhao Deng, Shu-Chai Zhu, Wen-Bin Shen
Publikováno v:
Discover Oncology, Vol 14, Iss 1, Pp 1-11 (2023)
Abstract Objective This study was designed to investigate the efficacy and prognostic factors for immune checkpoint inhibitors (ICIs) combined with or without radio(chemo)therapy and to evaluate their toxicity in patients with locally advanced or rec
Externí odkaz:
https://doaj.org/article/3f5ce182deaf4f4fb76f2cfe2c3aa7cb
Autor:
Bo Zhang, Xuetao Shi, Kai Cui, Zhongchao Li, Lei Li, Zhaogang Liu, Chengsheng Zhang, Pengfei Sun, Jingtao Zhong, Zhicheng Sun, Zhibin Chang, Zhao Ma, Alex Gordon-Weeks, Mingming Li, Lei Zhao
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-14 (2023)
Abstract Aim To understand the proportion of uHCC (unresectable hepatocellular carcinoma) patients who achieve successful conversion resection in a high-volume setting with state of the art treatment options. Methods We retrospectively reviewed all H
Externí odkaz:
https://doaj.org/article/167238a9b3a9490c8540c0ee9eb01c9c
Autor:
Ze Mi, Yunshu Zhang, Zhichao Feng, Jiahao Liu, Jianmin Wu, Hongpei Tan, Xiaoqian Ma, Zhenguo Liu, Pengfei Rong
Publikováno v:
Artificial Cells, Nanomedicine, and Biotechnology, Vol 50, Iss 1, Pp 301-309 (2022)
Aim PD-1/PD-L1 inhibitors in combination with CTLA-4 inhibitors are being tested in a number of ongoing clinical trials. As a result, it is critical to fully comprehend the toxicity characteristics of adverse events in combination therapy. This study
Externí odkaz:
https://doaj.org/article/881ad1e718a74fc085d5ec377c15d68e
Autor:
Kate Young, Andreas M. Schmitt, Deborah Mukherji, Lavinia Spain, Manuela Schmidinger, Lisa M. Pickering
Publikováno v:
Société Internationale d’Urologie Journal, Vol 3, Iss 6, Pp 485-499 (2022)
Standard approved systemic treatment options for the management of renal cancer have entirely transformed in the last 15 years and now comprise molecularly targeted therapies against the vascular endothelial growth factor receptor (VEGFR) and the mam
Externí odkaz:
https://doaj.org/article/ee3043a63966443897daa5d94dbede12
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.